Zhi Li

Zhi Li

Auto-generated profile, based on publicly available information

Zhi Li

Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2014 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
WLWeijuan Li
Weijuan Li
ZLZhi Li
Zhi Li
YCYaoqi Chen
Yaoqi Chen
SLSonghai Li
Songhai Li
YLYuanyuan Lv
Yuanyuan Lv
YWYumiao Wei
Yumiao Wei
Our study intended to prove whether agonistic autoantibodies to angiotensin II type 1 receptor (AT1-AAs) exist in patients with coronary heart disease (CHD) and affect the human endothelial cell (HEC) by upregulating proinflammatory cytokines expression involved in NF-κB pathway. Antibodies were determined by chronotropic responses of cultured neonatal rat cardiomyocytes coupled with receptor-specific antagonists (valsartan and AT1-EC2) as described previously. Interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), and monocyte chemotactic protein-1 (MCP-1) expression were improved at both mRNA and protein levels in HEC, while NF-κB in the DNA level was improved detected by electrophoretic mobility shift assays (EMSA). These improvements could be inhibited by specific AT1 receptor blocker valsartan, NF-κB blocker pyrrolidine dithiocarbamate (PDTC), and specific short peptides from the second extracellular loop of AT1 receptor. These results suggested that AT1-AAs, via the AT1 receptor, induce expression of proinflammatory cytokines involved in the activation of NF-κB. AT1-AAs may play a great role in the pathogenesis of the acute coronary syndrome by mediating vascular inflammatory effects involved in the NF-κB pathway.

31 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JDJingxia Du
Jingxia Du
WHWei He
Wei He
CZCai Zhang
Cai Zhang
JWJianzhao Wu
Jianzhao Wu
ZLZhi Li
Zhi Li
GLGaofeng Liang
Gaofeng Liang
Objective. Obesity causes a variety of metabolic alterations that may contribute to abnormalities of the cardiac structure and function (obesity cardiomyopathy). In previous works, we have shown that pentamethylquercetin (PMQ) significantly improved metabolic disorders in obese mice and it inhibited pressure overload‐induced cardiac remodeling in mice. However, its potential benefit in obesity cardiomyopathy remains unclear. The aim of this study was to investigate the effects of PMQ on cardiac remodeling in obese mice. Methods. We generated a monosodium glutamate‐induced obese (MSG‐IO) model in mice, which were treated with PMQ (5, 10, and 20 mg/kg) for 16 weeks consecutively. We examined the metabolic parameters and observed cardiac remodeling by performing cardiac echocardiography and Masson’s staining. The expression levels of molecules associated with the endogenous antioxidant system, including the sestrins/kelch‐like ECH‐associated protein 1 (Keap1)/Nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) signaling pathway, were analyzed by western blotting and immunofluorescent staining. Results. We found that PMQ treatment significantly ameliorated obesity phenotypes and improved metabolic disorders in MSG‐IO mice. PMQ decreased the heart wall thickness and attenuated cardiac fibrosis. Further study revealed that the protective effects of PMQ might be mediated by promoting Keap1 degradation and augmenting sestrins expression and Nrf2 nuclear translocation. Conclusion. Our findings indicated that PMQ ameliorated cardiac remodeling in obese mice by targeting the sestrins/Keap1/Nrf2 signaling pathway.

11 August 2012 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
YWYumiao Wei
Yumiao Wei
YCYaoqi Chen
Yaoqi Chen
ZLZhi Li
Zhi Li
WZWenping Zhou
Wenping Zhou
YLYuanyuan Lv
Yuanyuan Lv
YLYuhua Liao
Yuhua Liao